Tags

Type your tag names separated by a space and hit enter

[The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy].
Rev Neurol. 2006 Aug 1-15; 43(3):132-6.RN

Abstract

INTRODUCTION

The cerebral palsy has the first place of physical handicap in children (type spastic, 88%). Tizanidine imidazole derivative is centrally acting as a a2-adrenergic agonist.

AIM

To demonstrate clinically the effectiveness of tizanidine in the decrease of the spasticity.

PATIENTS AND METHODS

We assigned randomly in a double blind study 10 children treated with tizanidine (0.05 mg/kg/day) and 30 with placebo for a 6-month period, after which they were unified in the group of tizanidine. The dependent variables were spasticity, Ashworth scale, posture tone scale, reflex scale and liver function test.

RESULTS

The spasticity and the reflex decreased in the group of tizanidine an 78.85% in comparison with a 7.64% in the group of placebo (p = 0.0001); in the monitoring of 6 months 35 patients reduced this to 78.2% (p= 0.0001). The duration of effectiveness of tizanidine in four patients was two months and they never returned to their appraisal basal. Without reported adverse effects, the liver function test remains normal.

CONCLUSION

Tizanidine produces a significant reduction of the spasticity in children without adverse effects, having a high percentage of acceptance to the prescribe dose.

Authors+Show Affiliations

División de Rehabilitación Pediátrica, Servicio de Parálisis Cerebral Infantil y Estimulación Temprana, Centro Nacional de Rehabilitación, Tlalpan, Mexico DF, Mexico. ascelayv@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Randomized Controlled Trial

Language

spa

PubMed ID

16871477

Citation

Vásquez-Briceño, A, et al. "[The Usefulness of Tizanidine. a One-year Follow-up of the Treatment of Spasticity in Infantile Cerebral Palsy]." Revista De Neurologia, vol. 43, no. 3, 2006, pp. 132-6.
Vásquez-Briceño A, Arellano-Saldaña ME, León-Hernández SR, et al. [The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy]. Rev Neurol. 2006;43(3):132-6.
Vásquez-Briceño, A., Arellano-Saldaña, M. E., León-Hernández, S. R., & Morales-Osorio, M. G. (2006). [The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy]. Revista De Neurologia, 43(3), 132-6.
Vásquez-Briceño A, et al. [The Usefulness of Tizanidine. a One-year Follow-up of the Treatment of Spasticity in Infantile Cerebral Palsy]. Rev Neurol. 2006 Aug 1-15;43(3):132-6. PubMed PMID: 16871477.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy]. AU - Vásquez-Briceño,A, AU - Arellano-Saldaña,M E, AU - León-Hernández,S R, AU - Morales-Osorio,M G, PY - 2006/7/28/pubmed PY - 2007/4/27/medline PY - 2006/7/28/entrez SP - 132 EP - 6 JF - Revista de neurologia JO - Rev Neurol VL - 43 IS - 3 N2 - INTRODUCTION: The cerebral palsy has the first place of physical handicap in children (type spastic, 88%). Tizanidine imidazole derivative is centrally acting as a a2-adrenergic agonist. AIM: To demonstrate clinically the effectiveness of tizanidine in the decrease of the spasticity. PATIENTS AND METHODS: We assigned randomly in a double blind study 10 children treated with tizanidine (0.05 mg/kg/day) and 30 with placebo for a 6-month period, after which they were unified in the group of tizanidine. The dependent variables were spasticity, Ashworth scale, posture tone scale, reflex scale and liver function test. RESULTS: The spasticity and the reflex decreased in the group of tizanidine an 78.85% in comparison with a 7.64% in the group of placebo (p = 0.0001); in the monitoring of 6 months 35 patients reduced this to 78.2% (p= 0.0001). The duration of effectiveness of tizanidine in four patients was two months and they never returned to their appraisal basal. Without reported adverse effects, the liver function test remains normal. CONCLUSION: Tizanidine produces a significant reduction of the spasticity in children without adverse effects, having a high percentage of acceptance to the prescribe dose. SN - 0210-0010 UR - https://www.unboundmedicine.com/medline/citation/16871477/[The_usefulness_of_tizanidine__A_one_year_follow_up_of_the_treatment_of_spasticity_in_infantile_cerebral_palsy]_ L2 - http://www.revneurol.com/LinkOut/formMedLine.asp?Refer=2005414&Revista=RevNeurol DB - PRIME DP - Unbound Medicine ER -